- Home » News and Events

NEWS & EVENTS
Our newest offerings and capabilities. Recent investments in network capacity, new and expanded services and expertise. Upcoming conferences and events.
Catalent and JLABS Symposium to Discuss Accelerated Development and Manufacturing of Biologics
Jun 7, 2023
Experts and speakers from Catalent and JLABS will be joined by speakers from Johnson & Johnson and Cardiff Advisory LLC.
Catalent Expands OneBio® Suite for Integrated Development, Manufacturing and Supply Across Biologic Modalities
Jun 5, 2023
OneBio Suite offers customers an integrated service to accelerate programs from development to manufacturing, including fill/finish and packaging, and support for clinical supply and commercial launch.
Catalent and Bhami Research Laboratory Enter into Licensing Agreement for Technology to Deliver High-Concentration Biologics Subcutaneously
Mar 16, 2023
Under the terms of the agreement, Catalent is authorized to collaborate with its customers to evaluate BRL’s formulation technology to reduce viscosity and deliver high-concentration biologic products.
Catalent Expands UpTempo℠ AAV Platform to Accelerate Development of Gene Therapies
Mar 9, 2023
Catalent today announced the expansion of its UpTempo℠ platform process for the development and CGMP manufacturing of adeno-associated viral (AAV) vectors.
Catalent Completes Commercial-Scale Plasmid DNA Manufacturing Facility in Gosselies, Belgium
Jan 26, 2023
The state-of-the-art facility contains development and manufacturing space across multiple cleanrooms for the dedicated production of CGMP-grade pDNA for clinical and commercial-phase supply
Catalent Launches New Service for End-to-End Supply Chain Case Management of Cell and Gene Therapies
Jan 24, 2023
The new Case Management Service addresses challenges associated with delivering advanced therapies to patients by providing supply chain oversight from program start to finish.
Catalent Appoints Ricardo Zayas as North American Biologics Operations Leader
Jan 17, 2023
Mr. Zayas will be responsible for Catalent’s North American biologics operations. He will serve on the Executive Leadership Team, reporting directly to President & CEO, Alessandro Maselli.
Sarepta and Catalent Expand Strategic Manufacturing Partnership
Jan 5, 2023
Catalent and Sarepta sign an agreement to manufacture delandistrogene moxeparvovec, Sarepta’s most advanced gene therapy candidate for the treatment of Duchenne muscular dystrophy.
Catalent to Expand Its Biologics Analytical Services with New Facility in Durham, North Carolina
Dec 14, 2022
The new facility within North Carolina’s Research Triangle, will offer comprehensive analytical development and testing for biologic drug modalities.
Advanced Analytical Strategies for Large Molecules
Date: December 7, 2023
Automating Cell-Based Assays, Reducing Variability and Time to Results
Date: December 14, 2023
New GMP iPSC Lines and Improved Differentiation Workflows for Cell Therapy
Date: December 14, 2023